Introduction/Background The relationship between the circulating number of platelets and the evolution of ovarian cancer patients has been widely studied so far. The aim of the current study is to investigate whether a positive relation can be established between platelet count and the long term outcomes in both advanced stage and relapsed ovarian cancer.

Methodology Between 2014–2020 83 patients were submitted to surgery for advanced stage or relapsed ovarian cancer in Ion Cantacuzino hospital. In all cases preoperative hemograms were reviewed as well as the completeness of cytoreduction and the long term outcomes.

Results At the time of the primary cytoreduction the mean number of platelets was of 445.000/microl while at the time of the secondary cytoreduction this value was of 327.100/microl. At the time of primary cytoreduction cases in which complete cytoreduction was not feasible reported a significantly higher number of circulating platelets when compared to cases in which maximal debulking was possible (525.000/microl versus 383.000/microl, p=0,002). At the time of secondary cytoreduction cases in which complete debulking was feasible reported a mean number of platelets of 315.000/microl while cases in which debulking was incomplete reported a mean number of platelets of 345.000/microl, p=0,34. As expected, a statistically significant correlation was observed between the preoperative number of platelets and the overall survival at the time of primary cytoreduction; however, this correlation failed to be demonstrated at the time of secondary cytoreduction. We consider that these results are argued by the fact that at the time of relapse a significant number of cases present a lower number of platelets caused by the long history of systemic therapies which usually inhibit the function of synthesis of the marrow.

Conclusion Platelet count can be considered as a prognostic marker in advanced stage ovarian cancer but not in relapsed ovarian tumors.

Disclosures None.